These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
400 related articles for article (PubMed ID: 25801708)
1. A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study. Ciccaglione AF; Cellini L; Grossi L; Manzoli L; Marzio L Helicobacter; 2015 Oct; 20(5):390-6. PubMed ID: 25801708 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection. Zheng Q; Pan Y; Zhang L; Xiao SD Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231 [TBL] [Abstract][Full Text] [Related]
3. Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies. Ciccaglione AF; Tavani R; Grossi L; Cellini L; Manzoli L; Marzio L Helicobacter; 2016 Oct; 21(5):375-81. PubMed ID: 26807668 [TBL] [Abstract][Full Text] [Related]
4. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study. Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121 [TBL] [Abstract][Full Text] [Related]
5. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication. Akyildiz M; Akay S; Musoglu A; Tuncyurek M; Aydin A Eur J Intern Med; 2009 Jan; 20(1):53-7. PubMed ID: 19237093 [TBL] [Abstract][Full Text] [Related]
6. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592 [TBL] [Abstract][Full Text] [Related]
7. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication. Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386 [TBL] [Abstract][Full Text] [Related]
8. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366 [TBL] [Abstract][Full Text] [Related]
9. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Cao Z; Chen Q; Zhang W; Liang X; Liao J; Liu W; Xiao S; Lu H Scand J Gastroenterol; 2015; 50(10):1185-90. PubMed ID: 25881966 [TBL] [Abstract][Full Text] [Related]
10. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Wang Z; Wu S Singapore Med J; 2012 Apr; 53(4):273-6. PubMed ID: 22511052 [TBL] [Abstract][Full Text] [Related]
11. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120 [TBL] [Abstract][Full Text] [Related]
12. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS; Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562 [TBL] [Abstract][Full Text] [Related]
13. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161 [TBL] [Abstract][Full Text] [Related]
14. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg). Nyssen OP; Perez-Aisa A; Rodrigo L; Castro M; Mata Romero P; Ortuño J; Barrio J; Huguet JM; Modollel I; Alcaide N; Lucendo A; Calvet X; Perona M; Gomez B; Gomez Rodriguez BJ; Varela P; Jimenez-Moreno M; Dominguez-Cajal M; Pozzati L; Burgos D; Bujanda L; Hinojosa J; Molina-Infante J; Di Maira T; Ferrer L; Fernández-Salazar L; Figuerola A; Tito L; de la Coba C; Gomez-Camarero J; Fernandez N; Caldas M; Garre A; Resina E; Puig I; O'Morain C; Megraud F; Gisbert JP Helicobacter; 2020 Oct; 25(5):e12722. PubMed ID: 32656898 [TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999 [TBL] [Abstract][Full Text] [Related]
16. Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. Ghadir MR; Shafaghi A; Iranikhah A; Pakdin A; Joukar F; Mansour-Ghanaei F Turk J Gastroenterol; 2011 Feb; 22(1):1-5. PubMed ID: 21480103 [TBL] [Abstract][Full Text] [Related]
17. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC; Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865 [TBL] [Abstract][Full Text] [Related]
18. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial. Lu B; Wang J; Li J; Liu L; Chen Y Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194 [TBL] [Abstract][Full Text] [Related]
19. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. Luo L; Ji Y; Yu L; Huang Y; Liang X; Graham DY; Lu H Dig Dis Sci; 2020 Dec; 65(12):3639-3646. PubMed ID: 32020360 [TBL] [Abstract][Full Text] [Related]
20. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection. Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]